Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis.
BACKGROUND
Despite supplementation with standard multivitamins and pancreatic enzymes, deficiencies of vitamins D and K and antioxidants are common in cystic fibrosis (CF).


METHODS
In this non-randomized, open-label study, AquADEKs® softgels were given daily over 12 weeks to 14 CF subjects (mean age 15 years, range 10-23) without a preceding wash-out period. Both pancreatic sufficient and insufficient subjects were enrolled. Plasma vitamin and antioxidant levels, urine 8-isoprostane levels, anthropometric measures, and pulmonary function were determined at baseline, 6 and 12 weeks.


RESULTS
Daily supplementation significantly increased plasma beta(β)-carotene, coenzyme Q10, and γ-tocopherol concentrations, decreased proteins induced in vitamin K absence (PIVKA-II) levels, but did not normalize vitamin D and K status in all subjects. Vitamin A levels did not exceed the normal range for any subject during the entire study period. Modest improvements in weight percentile and pulmonary function were observed. Change in plasma β-carotene concentrations weakly correlated with changes in weight and body mass index percentiles.


CONCLUSIONS
In this study, AquADEKs® increased systemic antioxidant levels, while maintaining vitamin A levels in the normal range, and improved but did not completely normalize vitamin D and K status. Increased β-carotene levels were associated with improved growth parameters. These results warrant further clinical evaluation in CF.
Sagel
Scott D
SD
Department of Pediatrics, The Children's Hospital, University of Colorado Denver School of Medicine, Aurora, CO, USA. sagel.scott@tchden.org
Sontag
Marci K
MK
Anthony
Meg M
MM
Emmett
Peggy
P
Papas
Konstantinos A
KA
D000293:Adolescent; D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use; D054316:Biomarkers, Pharmacological; D015992:Body Mass Index; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D019587:Dietary Supplements / Q000009:adverse effects; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D010188:Exocrine Pancreatic Insufficiency / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D012129:Respiratory Function Tests; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use; D014802:Vitamin A Deficiency / Q000097:blood / Q000209:etiology / Q000628:therapy*; D014808:Vitamin D Deficiency / Q000097:blood / Q000209:etiology / Q000628:therapy*; D014813:Vitamin K Deficiency / Q000097:blood / Q000209:etiology / Q000628:therapy*; D014815:Vitamins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D055815:Young Adult
D000975:Antioxidants; D054316:Biomarkers, Pharmacological; D014815:Vitamins; D014451:Ubiquinone; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; C024989:coenzyme Q10